The Content Crisis, the Trust Shift and the Case for Co-Creation
The key takeaways from Reuters Pharma Europe 2026 and Pharma meets AI (UBIQ Events)
Pharma has never produced more content. It has never invested more in AI. And it has never been further from solving the fundamental problem: making its messages land with the people who need to hear them.
That was the thread running through Reuters Pharma Europe 2026 in Barcelona and the Pharma meets AI conference hosted by UBIQ Events. The tools are more powerful than ever, the content pipelines are overflowing, and yet HCPs are disengaged, patients feel unheard, and field teams are ignoring three quarters of what gets produced. Here is what stood out:
1. AI has not delivered the productivity gains pharma was promised
The parallel with history is hard to ignore. In 1987, Nobel laureate Robert Solow observed that computers appeared everywhere except in the productivity statistics. Productivity growth had dropped from 2.9% between 1948 and 1973 to just 1.1% thereafter. Nearly four decades on, AI finds itself in the same position, despite an estimated global investment of $250 billion in 2024 alone.
At Pharma meets AI, the jury remained firmly out on whether AI-augmented drug discovery and development would deliver a favourable productivity-to-cost ratio. The dominant rhetoric pointed to higher productivity opportunities afforded by unprecedented volumes of scientific data. But the counterargument was equally compelling: the sheer volume of possibilities opened up by AI could represent a resource drain rather than a saving.
The consensus at both conferences was that pharma needs to split work intelligently before throwing AI at it: core human work requiring judgement and accountability, augmented work involving genuine human-AI collaboration, and automated work that frees up time. Most organisations have not yet made this distinction, and until they do, AI will continue to accelerate existing dysfunction rather than resolve it.
2. The content flood is rising, but nobody is swimming
Pharma produced 29% more content in 2025 than the year before. Yet 77% of approved assets are rarely or never used by field teams. Pre-review timelines stretch from 5 to 150 days per asset before content even reaches MLR. As one former content factory lead put it: we are at risk of scaling the problem with AI.
Many pharma companies want to move away from monthly retainers and hourly rates, recognising that the traditional agency model is not fit for purpose. But going it alone with AI is not sustainable either. GenAI can produce a first draft, but without experienced medical editors to check accuracy, ensure compliance and humanise the tone, that draft risks becoming soulless content that fails to resonate.
Industry leaders pointed to modular content as the path forward: pre-approved atomic pieces linked to claims and references, adaptable locally and deployable across multiple channels. But the prerequisites are non-negotiable. Without taxonomy, metadata and adequate governance in place, AI processes will only reveal where the structural homework was not done.
3. The HCP trust model has fundamentally shifted
Seven in ten HCPs want more personalised medical interactions. 40% are less likely to engage when content is not tailored to their needs. Meanwhile, the source of trust has fundamentally changed: the old top-down authority model has given way to peer-to-peer influence and social media engagement. 61% of HCPs regularly scan social media for professional information, and 41% report changing their prescribing behaviour based on content shared on social platforms.
New approaches are moving away from the traditional KOL-driven model towards identifying tightly knit clusters of HCPs who influence one another. Companies that close this personalisation gap see 30% more HCP engagement from omnichannel orchestration, alongside 5 to 10% revenue uplift and 10 to 20% marketing efficiency gains.
4. Patients need clarity, not more information.
A patient tells his doctor he has no chewing problems. He just quietly stopped eating steak months ago. Standard questionnaires did not catch it. AI tools did not catch it. Only a doctor noticing a hesitation mid-answer brought it to light.
For rare diseases, the challenge intensifies. Expertise is fragmented across countries, languages and specialties. Patients adapt so completely to their conditions that they no longer register what they have lost. Yet consent forms remain too complex, and the industry too often designs engagement strategies for patients rather than alongside them. Patients do not want more content. They want to understand what is happening to them and what to do next. Doctors do not want another digital platform. They want tools that connect clinical data to real patient lives.
5. Co-creation is the only thing that works
When patients, HCPs and pharma build together, the outcomes are measurably better. “In My Shoes”, an immersive application co-created by patients and doctors, lets clinical teams experience 24 to 48 hours as a patient. The process of co-creation itself was the breakthrough, not the technology behind it.
Patient organisations are also building real-world evidence platforms that capture what clinical scales miss: daily burden, quality of life, fatigue and mental health data across the full treatment journey. Research consistently shows that co-created digital tools are significantly more usable and clinically relevant in practice.
Pharma’s role is evolving from promoter to facilitator. Perhaps the most honest thing the industry can do is stop asking “how do we reach patients” and start asking “what are we building together, and with whom?”
Where SciencePOD fits
These conference insights point to a single conclusion: pharma needs a content partner that understands the science, respects the compliance requirements and delivers content that actually resonates with HCPs and patients.
At SciencePOD, we map out your content needs across videos, articles, infographics and podcasts over 6 or 12 month periods. Every asset is created or quality-checked by professional medical editors and subjected to pre-MLR review.
We offer both premium content from experienced medical writers and GenAI-hybrid content, editorially refined. Both are compliant. Both use storytelling to ensure your content compels as well as informs. You pay only for the content pack you need. No retainer. No hourly fees.